Drug Trial Radar · NCT02049957
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Feb 8, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
118
Actual
Start
Feb 13, 2014
Primary completion
Jun 29, 2018
Study completion Jun 29, 2018
Sponsor
- Lead sponsor
- Calithera Biosciences, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 30, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1b/2 study of the safety and efficacy of sapanisertib (MLN0128) in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced or metastatic breast cancer who progressed on treatment with everolimus in combination with exemestane or fulvestrant.
Conditions
- Breast Cancer
Interventions
SapanisertibDrug
Sapnisertib capsules
FulvestrantDrug
Fulvestrant IM injection.
ExemestaneDrug
Exemestane tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: First dose of study drug through 30 days after the last dose (Up to 52 months)
- Phase 2: Clinical Benefit Rate at 16 Weeks (CBR-16)Time frame: Week 16
Locations
40 sites in 3 countries. Site status is shown where the registry gives one.
Los Angeles Hematology
Los Angeles, California
University of California at San Francisco (PARENT)
San Francisco, California
Santa Barbara Hematology Oncology Medical Group, Inc.
Santa Barbara, California
University of Colorado Cancer Center
Aurora, Colorado
Rocky Mountain Cancer Centers, LLP
Lakewood, Colorado
Mount Sinai Medical Center
Miami Beach, Florida
Florida Cancer Research Institute
Plantation, Florida
University of Kansas Medical Center Research Institute, Inc.
Westwood, Kansas
Holy Cross Hospital
Silver Spring, Maryland
Henry Ford Medical Center
Novi, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Roswell Park Cancer Institute
Buffalo, New York
Herbert Irving Comprehensive Cancer Center
New York, New York
Weill Cornell Medical College New York Presbyterian Hospital
New York, New York
Eastchester Center for Cancer Care / BRANY
The Bronx, New York
University of Cincinnati Physicians Company, LLC
Cincinnati, Ohio
University Hospitals of Cleveland
Cleveland, Ohio
Erlanger Medical Center
Chattanooga, Tennessee
Texas Oncology, P.A. - Beaumont
Beaumont, Texas
Texas Oncology, P.A.
Dallas, Texas
UT Southwestern Medical Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Millennium Oncology
Houston, Texas
Texas Health Physicians Group
Plano, Texas
Cancer Care Network of South Texas - SAT&BC
San Antonio, Texas
Texas Oncology, P.A. - Tyler
Tyler, Texas
Virginia Oncology Associates - Hampton
Chesapeake, Virginia
Oncology and Hematology Assoc. of SW VA, Inc.
Salem, Virginia
West Virginia University
Morgantown, West Virginia
UZ Antwerpen
Antwerp, Belgium
Institut Jules Bordet
Brussels, Belgium
Universitair Ziekenhuis Brussel
Brussels, Belgium
GHdC Notre Dame
Charleroi, Belgium
Centre Hospitalier de l'Ardenne
Libramont, Belgium
GZA Ziekenhuizen - Campus Sint-Augustinus
Wilrijk, Belgium
Centre Francois Baclesse
Caen, Calvados, France
Centre Catherine de Sienne
Nantes, Loire Atlantique, France
Clinique Victor Hugo - Centre Jean Bernard
Le Mans, Sarthe, France
Institut Sainte Catherine
Avignon, Vaculuse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.